GSK (GSK) Competitors $36.62 -0.34 (-0.91%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$36.50 -0.12 (-0.34%) As of 02/21/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GSK vs. AZN, NVS, SNY, TAK, ARGX, BNTX, ONC, TEVA, SMMT, and GMABShould you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Novartis (NVS), Sanofi (SNY), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry. GSK vs. AstraZeneca Novartis Sanofi Takeda Pharmaceutical argenx BioNTech Beigene Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S GSK (NYSE:GSK) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability. Is GSK or AZN a better dividend stock? GSK pays an annual dividend of $1.48 per share and has a dividend yield of 4.0%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 2.8%. GSK pays out 93.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 91.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Which has stronger valuation & earnings, GSK or AZN? AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGSK$40.10B1.89$3.29B$1.5923.03AstraZeneca$54.07B4.26$7.04B$2.2632.83 Do analysts recommend GSK or AZN? GSK presently has a consensus target price of $43.25, suggesting a potential upside of 18.09%. AstraZeneca has a consensus target price of $89.75, suggesting a potential upside of 20.96%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 0 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 3 Strong Buy rating(s) 2.60AstraZeneca 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 Do institutionals and insiders hold more shares of GSK or AZN? 15.7% of GSK shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, GSK or AZN? GSK has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Does the media prefer GSK or AZN? In the previous week, AstraZeneca had 20 more articles in the media than GSK. MarketBeat recorded 56 mentions for AstraZeneca and 36 mentions for GSK. AstraZeneca's average media sentiment score of 0.42 beat GSK's score of 0.38 indicating that AstraZeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 15 Very Positive mention(s) 5 Positive mention(s) 15 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AstraZeneca 28 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community believe in GSK or AZN? GSK received 760 more outperform votes than AstraZeneca when rated by MarketBeat users. However, 59.62% of users gave AstraZeneca an outperform vote while only 57.12% of users gave GSK an outperform vote. CompanyUnderperformOutperformGSKOutperform Votes82257.12% Underperform Votes61742.88% AstraZenecaOutperform Votes6259.62% Underperform Votes4240.38% Is GSK or AZN more profitable? AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.13%. GSK's return on equity of 48.59% beat AstraZeneca's return on equity.Company Net Margins Return on Equity Return on Assets GSK8.13% 48.59% 11.11% AstraZeneca 13.01%32.23%12.31% SummaryAstraZeneca beats GSK on 15 of the 21 factors compared between the two stocks. Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GSK vs. The Competition Export to ExcelMetricGSKPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$75.91B$7.04B$5.77B$20.07BDividend Yield4.04%2.87%4.78%3.65%P/E Ratio23.036.1326.4634.90Price / Sales1.89309.83453.2515.64Price / Cash6.2567.8344.0420.85Price / Book4.546.747.634.92Net Income$3.29B$138.11M$3.18B$1.02B7 Day Performance1.19%-2.43%-1.91%-1.05%1 Month Performance9.53%-1.91%-0.19%-1.09%1 Year Performance-13.13%-5.03%16.70%13.70% GSK Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GSKGSK3.2617 of 5 stars$36.62-0.9%$43.25+18.1%-12.7%$75.91B$40.10B23.0370,200Gap DownAZNAstraZeneca2.4169 of 5 stars$73.58-1.2%$89.75+22.0%+14.0%$228.18B$54.07B32.5689,900Options VolumeNVSNovartis3.018 of 5 stars$105.43-2.1%$123.38+17.0%+6.7%$215.50B$50.32B17.9376,057Positive NewsSNYSanofi4.1298 of 5 stars$54.50+0.9%$60.00+10.1%+13.6%$138.31B$44.46B21.8986,088Analyst RevisionPositive NewsTAKTakeda Pharmaceutical2.5882 of 5 stars$13.54-0.6%N/A-4.4%$43.07B$28.20B33.8449,281ARGXargenx2.525 of 5 stars$639.41-1.8%$658.39+3.0%+61.1%$38.85B$1.27B-726.601,148News CoveragePositive NewsBNTXBioNTech2.3788 of 5 stars$119.83-2.4%$142.72+19.1%+29.4%$28.73B$4.13B-57.066,133Positive NewsGap DownONCBeigeneN/A$230.86+2.4%N/AN/A$22.56B$2.46B-28.0210,600Insider TradeNews CoverageGap UpTEVATeva Pharmaceutical Industries2.891 of 5 stars$16.24-2.4%$23.57+45.2%+28.8%$18.39B$16.54B-11.2037,851SMMTSummit Therapeutics2.3033 of 5 stars$21.37-2.1%$33.57+57.1%+438.2%$15.76B$700,000.00-76.32110Gap UpGMABGenmab A/S4.5899 of 5 stars$21.30+1.8%$42.17+98.0%-22.8%$14.10B$2.39B20.682,204 Related Companies and Tools Related Companies AstraZeneca Competitors Novartis Competitors Sanofi Competitors Takeda Pharmaceutical Competitors argenx Competitors BioNTech Competitors Beigene Competitors Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Genmab A/S Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:GSK) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.